查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836372

2032 年先进癌症诊断市场预测：按产品类型、癌症类型、技术、分销管道、应用、最终用户和地区进行全球分析

Advanced Cancer Diagnostics Market Forecasts to 2032 - Global Analysis By Product Type (Instruments, Consumables, Software & Services, and Other Product Types), Cancer Type, Technology, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球先进癌症诊断市场预计在 2025 年达到 641.3 亿美元，到 2032 年将达到 1,249.7 亿美元，预测期内的复合年增长率为 10.0%。

先进的癌症诊断涵盖用于早期癌症检测、肿瘤生物学分析和个人化治疗策略的最新技术和方法。这些技术和方法包括生物标记分析、基因检测、高阶成像和分子分析等工具。这些诊断方法能够准确检测癌症，改善预后并减少治疗併发症。透过支持标靶治疗和精准干预措施的开发，先进的诊断技术能够显着改善患者护理、提高存活率和整体治疗效果。

全球癌症发生率上升

随着人口老化和生活方式相关风​​险因素的增加，早期检测技术已成为临床工作流程的关键。医疗保健系统正在投资精准肿瘤学工具，例如液态切片和分子成像，以提高诊断准确性。人工智慧病理检测和次世代定序仪(NGS) 的创新正在促成个人化治疗策略。多体学平台的整合正在将癌症诊断转变为一门数据驱动的学科。日益增长的癌症负担正在刺激已开发经济体和新兴经济体的市场发展。

复杂且限制性的报销政策

先进癌症诊断的报销框架仍然碎片化，这常常阻碍其广泛应用。付款方通常需要大量的临床检验和成本效益数据，才能核准新的诊断测试。人工智慧和基因组技术的加入增加了监管的复杂性，减缓了报销核准。资源和专业知识有限的小型诊断公司在应对这些政策方面面临挑战。这些限制可能会延迟患者获得尖端诊断工具的机会，并扼杀创新。全球报销标准的协调对于充分发挥精准诊断的潜力至关重要。

扩展诊断能力

诊断技术的快速发展正在开闢癌症检测和监测的新领域。液态切片平台、人工智慧成像和即时生物标记分析正在彻底改变临床医生识别恶性肿瘤的方式。向非侵入式照护现场诊断的转变正在提高患者舒适度和操作效率。新兴趋势包括穿戴式生物感测器和云端基础的诊断平台，可实现远端癌症筛检。监管机构正透过加速核准途径和数位健康倡议加强对创新的支持。这些发展为市场成长和跨部门合作创造了肥沃的土壤。

假阳性/阴性的风险

假阳性可能导致不必要的治疗和情绪困扰，而假阴性则会延误挽救生命的干预措施。不同平台的检测灵敏度和特异性有差异，导致结果不一致。人工智慧演算法前景广阔，但需要严格的检验才能确保临床可靠性。监管机构正在加强诊断效能和数据透明度的标准。应对这些风险对于维护信任和安全地整合新兴技术至关重要。

COVID-19的影响：

新冠疫情扰乱了癌症诊断服务，延误了筛检，并降低了患者吞吐量。封锁和资源重新分配使实验室运作和供应链紧张，导致检测短缺。然而，这场危机加速了远距离诊断、远距病理学和人工智慧分诊系统的采用。紧急使用授权使得创新诊断工具在疫情期间得以快速部署。后疫情时代，策略强调韧性、自动化和分散式检查模式。这些转变正在重塑癌症诊断格局，更加重视数位转型和应对准备。

预计在预测期内，消耗品部分将占据最大份额

由于耗材在常规诊断程序中发挥重要作用，预计在预测期内将占据最大的市场份额。试剂、检测试剂套件和样品製备工具对于分子和免疫组织化学测试至关重要。试剂配方和微流体盒的不断创新正在提高测试的灵敏度和通量。个人化医疗的兴起推动了针对个别癌症特征的专用耗材的需求。实验室工作流程的自动化正在增加集中式和分散式耗材的使用。随着全球诊断数量的增加，耗材仍是癌症检测基础设施的支柱。

预计在预测期内，医院和诊所部门的复合年增长率最高。

医院和诊所领域预计将在预测期内实现最高成长率，这得益于其在癌症诊断和治疗中的核心作用。这些机构正在迅速采用先进的成像系统、基于人工智慧的病理学工具和整合诊断平台。对早期检测和精准肿瘤学的追求正在推动对内部诊断能力的投资。医院也在利用云端基础的数据分析来简化工作流程并提高诊断准确性。新兴趋势包括配备即时决策支援系统的混合诊断实验室和多学科癌症中心。随着患者人数的增加，医院和诊所正成为癌症诊断创新的中心。

比最大的地区

受医疗基础设施扩张和癌症发病率上升的推动，亚太地区预计将在预测期内占据最大的市场份额。中国、印度和日本等国家正大力投资诊断现代化和本地製造。政府正在推动早期癌症筛检，并津贴先进的诊断技术。该地区正见证人工智慧辅助成像和可携式诊断设备的快速普及。全球科技公司与本地医疗服务提供者之间的策略合作伙伴关係正在加速创新和市场渗透。

复合年增长率最高的地区：

在预测期内，北美预计将呈现最高的复合年增长率，这得益于其在诊断创新和研究资金方面的领先地位。美国和加拿大正在率先开发基因组分析、人工智慧诊断和智慧实验室系统。监管机构正在简化尖端诊断工具的核准流程，以加快其市场准入速度。医院正在整合物联网和云端基础平台，以提高诊断准确性和营运效率。该地区受益于强大的报销生态系统和个人化医疗的高度普及。随着癌症治疗日益以数据主导，北美将继续在诊断卓越性方面树立全球标竿。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球高级癌症诊断市场（依产品类型）

  • 装置
    • 影像系统
    • 基于病理学的仪器
    • 分子诊断平台
  • 耗材
    • 套件和试剂
    • 检测组
  • 软体和服务
    • 数据分析工具
    • 诊断服务
  • 其他产品类型

第六章全球高级癌症诊断市场（按癌症类型）

  • 乳癌
  • 肝癌
  • 肺癌
  • 子宫颈癌
  • 大肠直肠癌
  • 卵巢癌
  • 摄护腺癌
  • 其他癌症

7. 全球先进癌症诊断市场（按技术）

  • 影像技术
    • MRI
    • PET/CT
    • 电脑断层扫描
    • 超音波
    • 乳房X光检查
  • 分子诊断
    • PCR
    • 微阵列
    • 次世代定序（NGS）
    • 原位杂交（ISH）
  • 免疫检测
    • ELISA
    • 免疫组织化学（IHC）
  • 液态生物检体
    • 循环性肿瘤细胞（CTC）
    • 循环肿瘤DNA（ctDNA）
    • 外泌体
  • 其他技术

8. 全球高级癌症诊断市场（按分销管道）

  • 直销
  • 分销商和经销商
  • 线上平台

9. 全球先进癌症诊断市场（按应用）

  • 早期癌症筛检
  • 检测復发和微量残存疾病（MRD）
  • 诊断和预后测试
  • 伴随诊断
  • 治疗方法选择和监测
  • 其他用途

第 10 章全球进阶癌症诊断市场（按最终用户）

  • 医院和诊所
  • 门诊治疗中心
  • 诊断实验室
  • 癌症研究所
  • 其他最终用户

第 11 章全球高阶癌症诊断市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章：企业概况

  • F. Hoffmann-La Roche Ltd.
  • bioMerieux SA
  • Thermo Fisher Scientific Inc.
  • Medtronic plc
  • Abbott Laboratories
  • Becton, Dickinson and Company（BD）
  • Illumina Inc.
  • Myriad Genetics Inc.
  • GE Healthcare
  • Guardant Health
  • Siemens Healthineers
  • Qiagen NV
  • Bio-Rad Laboratories Inc.
  • Hologic Inc.
  • Agilent Technologies Inc.
Product Code: SMRC31496

According to Stratistics MRC, the Global Advanced Cancer Diagnostics Market is accounted for $64.13 billion in 2025 and is expected to reach $124.97 billion by 2032 growing at a CAGR of 10.0% during the forecast period. Advanced cancer diagnostics encompass modern techniques and technologies used to identify cancers early, analyze tumor biology, and personalize treatment decisions. They involve tools such as biomarker analysis, genetic testing, advanced imaging, and molecular profiling. These diagnostic methods allow for accurate cancer detection, improved prognosis, and reduced treatment complications. By supporting targeted therapy development and precise intervention, advanced diagnostics significantly enhance patient care, survival chances, and overall treatment effectiveness.

Market Dynamics:

Driver:

Rising global cancer incidence

As aging populations grow and lifestyle-related risk factors increase, early detection technologies are becoming essential in clinical workflows. Healthcare systems are investing in precision oncology tools, including liquid biopsies and molecular imaging, to improve diagnostic accuracy. Innovations in AI-powered pathology and next-generation sequencing (NGS) are enabling personalized treatment strategies. The integration of multi-omics platforms is transforming cancer diagnostics into a data-driven discipline. This rising burden of cancer is catalyzing market expansion across both developed and emerging economies.

Restraint:

Complex and restrictive reimbursement policies

Reimbursement frameworks for advanced cancer diagnostics remain fragmented and often hinder widespread adoption. Payers frequently require extensive clinical validation and cost-effectiveness data before approving coverage for novel diagnostic tests. The inclusion of AI and genomic technologies adds regulatory complexity, slowing reimbursement approvals. Smaller diagnostic firms face challenges navigating these policies due to limited resources and expertise. These constraints can delay patient access to cutting-edge diagnostic tools and stifle innovation. Harmonizing global reimbursement standards is critical to unlocking the full potential of precision diagnostics.

Opportunity:

Expanding diagnostic capabilities

Rapid advancements in diagnostic technologies are opening new frontiers in cancer detection and monitoring. Liquid biopsy platforms, AI-enhanced imaging, and real-time biomarker analysis are revolutionizing how clinicians identify malignancies. The shift toward non-invasive and point-of-care diagnostics is improving patient comfort and operational efficiency. Emerging trends include wearable biosensors and cloud-based diagnostic platforms that enable remote cancer screening. Regulatory bodies are increasingly supporting innovation through expedited approval pathways and digital health initiatives. These developments are creating fertile ground for market growth and cross-sector collaboration.

Threat:

Risk of false positives/negatives

False positives can lead to unnecessary treatments and psychological distress, while false negatives may delay life-saving interventions. Variability in test sensitivity and specificity across platforms contributes to inconsistent outcomes. AI algorithms, while promising, require rigorous validation to ensure clinical reliability. Regulatory agencies are tightening standards around diagnostic performance and data transparency. Addressing these risks is vital to maintaining trust and ensuring the safe integration of emerging technologies.

Covid-19 Impact:

The COVID-19 pandemic disrupted cancer diagnostic services, delaying screenings and reducing patient throughput. Lockdowns and resource reallocation strained laboratory operations and supply chains, leading to test shortages. However, the crisis accelerated the adoption of remote diagnostics, telepathology, and AI-driven triage systems. Emergency use authorizations enabled faster deployment of innovative diagnostic tools during the pandemic. Post-COVID strategies now emphasize resilience, automation, and decentralized testing models. These shifts are reshaping the cancer diagnostics landscape with a stronger focus on digital transformation and preparedness.

The consumables segment is expected to be the largest during the forecast period

The consumables segment is expected to account for the largest market share during the forecast period, due to its indispensable role in routine diagnostic procedures. Reagents, assay kits, and sample preparation tools are critical for molecular and immunohistochemical testing. Continuous innovation in reagent formulations and microfluidic cartridges is enhancing test sensitivity and throughput. The rise of personalized medicine is driving demand for specialized consumables tailored to individual cancer profiles. Automation in laboratory workflows is boosting consumable usage across centralized and decentralized settings. As diagnostic volumes increase globally, consumables remain the backbone of cancer testing infrastructure.

The hospitals & clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals & clinics segment is predicted to witness the highest growth rate, driven by their central role in cancer diagnosis and treatment. These facilities are rapidly adopting advanced imaging systems, AI-based pathology tools, and integrated diagnostic platforms. The push for early detection and precision oncology is fueling investment in in-house diagnostic capabilities. Hospitals are also leveraging cloud-based data analytics to streamline workflows and enhance diagnostic accuracy. Emerging trends include hybrid diagnostic labs and multidisciplinary cancer centers equipped with real-time decision support systems. As patient volumes rise, hospitals and clinics are becoming hubs for innovation in cancer diagnostics.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, supported by expanding healthcare infrastructure and rising cancer prevalence. Countries like China, India, and Japan are investing heavily in diagnostic modernization and local manufacturing. Government initiatives are promoting early cancer screening and subsidizing advanced diagnostic technologies. The region is witnessing rapid adoption of AI-assisted imaging and portable diagnostic devices. Strategic collaborations between global tech firms and regional healthcare providers are accelerating innovation and market penetration.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fueled by its leadership in diagnostic innovation and research funding. The U.S. and Canada are pioneering developments in genomic profiling, AI-powered diagnostics, and smart laboratory systems. Regulatory agencies are streamlining approval processes for cutting-edge diagnostic tools, encouraging faster market entry. Hospitals are integrating IoT and cloud-based platforms to enhance diagnostic precision and operational efficiency. The region benefits from a robust reimbursement ecosystem and high adoption of personalized medicine. As cancer care becomes increasingly data-driven, North America continues to set global benchmarks in diagnostic excellence.

Key players in the market

Some of the key players in Advanced Cancer Diagnostics Market include F. Hoffmann-La Roche Ltd., bioMerieux SA, Thermo Fisher Scientific Inc., Medtronic plc, Abbott Laboratories, Becton, Dickinson and Company (BD), Illumina Inc., Myriad Genetics Inc., GE Healthcare, Guardant Health, Siemens Healthineers, Qiagen N.V., Bio-Rad Laboratories Inc., Hologic Inc., and Agilent Technologies Inc.

Key Developments:

In September 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio, Inc. (Nasdaq: ETNB), a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio's pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients as well as cirrhotic patients.

In June 2025, bioMerieux announced an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance bioMerieux's capabilities in next-generation sequencing (NGS) and rapid diagnostics, further solidifying its commitment to advancing healthcare and Antimicrobial Stewardship through innovative solutions.

Product Types Covered:

  • Instruments
  • Consumables
  • Software and Services
  • Other Product Types

Cancer Types Covered:

  • Breast Cancer
  • Liver Cancer
  • Lung Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Other Cancers

Technologies Covered:

  • Imaging Techniques
  • Molecular Diagnostics
  • Immunoassays
  • Liquid Biopsy
  • Other Technologies

Distribution Channels Covered:

  • Direct Sales
  • Distributors & Dealers
  • Online Platforms

Applications Covered:

  • Early Cancer Screening
  • Recurrence & Minimal Residual Disease (MRD) Detection
  • Diagnostic & Prognostic Testing
  • Companion Diagnostics
  • Therapy Selection & Monitoring
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Diagnostic Laboratories
  • Cancer Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Advanced Cancer Diagnostics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Instruments
    • 5.2.1 Imaging Systems
    • 5.2.2 Pathology-based Instruments
    • 5.2.3 Molecular Diagnostic Platforms
  • 5.3 Consumables
    • 5.3.1 Kits & Reagents
    • 5.3.2 Assay Panels
  • 5.4 Software & Services
    • 5.4.1 Data Analytics Tools
    • 5.4.2 Diagnostic Services
  • 5.5 Other Product Types

6 Global Advanced Cancer Diagnostics Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 Breast Cancer
  • 6.3 Liver Cancer
  • 6.4 Lung Cancer
  • 6.5 Cervical Cancer
  • 6.6 Colorectal Cancer
  • 6.7 Ovarian Cancer
  • 6.8 Prostate Cancer
  • 6.9 Other Cancers

7 Global Advanced Cancer Diagnostics Market, By Technology

  • 7.1 Introduction
  • 7.2 Imaging Techniques
    • 7.2.1 MRI
    • 7.2.2 PET/CT
    • 7.2.3 CT Scan
    • 7.2.4 Ultrasound
    • 7.2.5 Mammography
  • 7.3 Molecular Diagnostics
    • 7.3.1 PCR
    • 7.3.2 Microarrays
    • 7.3.3 Next-Generation Sequencing (NGS)
    • 7.3.4 In Situ Hybridization (ISH)
  • 7.4 Immunoassays
    • 7.4.1 ELISA
    • 7.4.2 Immunohistochemistry (IHC)
  • 7.5 Liquid Biopsy
    • 7.5.1 Circulating Tumor Cells (CTCs)
    • 7.5.2 Circulating Tumor DNA (ctDNA)
    • 7.5.3 Exosomes
  • 7.6 Other Technologies

8 Global Advanced Cancer Diagnostics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Direct Sales
  • 8.3 Distributors & Dealers
  • 8.4 Online Platforms

9 Global Advanced Cancer Diagnostics Market, By Application

  • 9.1 Introduction
  • 9.2 Early Cancer Screening
  • 9.3 Recurrence & Minimal Residual Disease (MRD) Detection
  • 9.4 Diagnostic & Prognostic Testing
  • 9.5 Companion Diagnostics
  • 9.6 Therapy Selection & Monitoring
  • 9.7 Other Applications

10 Global Advanced Cancer Diagnostics Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals & Clinics
  • 10.3 Ambulatory Care Centers
  • 10.4 Diagnostic Laboratories
  • 10.5 Cancer Research Institutes
  • 10.6 Other End Users

11 Global Advanced Cancer Diagnostics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 F. Hoffmann-La Roche Ltd.
  • 13.2 bioMerieux SA
  • 13.3 Thermo Fisher Scientific Inc.
  • 13.4 Medtronic plc
  • 13.5 Abbott Laboratories
  • 13.6 Becton, Dickinson and Company (BD)
  • 13.7 Illumina Inc.
  • 13.8 Myriad Genetics Inc.
  • 13.9 GE Healthcare
  • 13.10 Guardant Health
  • 13.11 Siemens Healthineers
  • 13.12 Qiagen N.V.
  • 13.13 Bio-Rad Laboratories Inc.
  • 13.14 Hologic Inc.
  • 13.15 Agilent Technologies Inc.

List of Tables

  • Table 1 Global Advanced Cancer Diagnostics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Advanced Cancer Diagnostics Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Advanced Cancer Diagnostics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 4 Global Advanced Cancer Diagnostics Market Outlook, By Imaging Systems (2024-2032) ($MN)
  • Table 5 Global Advanced Cancer Diagnostics Market Outlook, By Pathology-based Instruments (2024-2032) ($MN)
  • Table 6 Global Advanced Cancer Diagnostics Market Outlook, By Molecular Diagnostic Platforms (2024-2032) ($MN)
  • Table 7 Global Advanced Cancer Diagnostics Market Outlook, By Consumables (2024-2032) ($MN)
  • Table 8 Global Advanced Cancer Diagnostics Market Outlook, By Kits & Reagents (2024-2032) ($MN)
  • Table 9 Global Advanced Cancer Diagnostics Market Outlook, By Assay Panels (2024-2032) ($MN)
  • Table 10 Global Advanced Cancer Diagnostics Market Outlook, By Software & Services (2024-2032) ($MN)
  • Table 11 Global Advanced Cancer Diagnostics Market Outlook, By Data Analytics Tools (2024-2032) ($MN)
  • Table 12 Global Advanced Cancer Diagnostics Market Outlook, By Diagnostic Services (2024-2032) ($MN)
  • Table 13 Global Advanced Cancer Diagnostics Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 14 Global Advanced Cancer Diagnostics Market Outlook, By Cancer Type (2024-2032) ($MN)
  • Table 15 Global Advanced Cancer Diagnostics Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 16 Global Advanced Cancer Diagnostics Market Outlook, By Liver Cancer (2024-2032) ($MN)
  • Table 17 Global Advanced Cancer Diagnostics Market Outlook, By Lung Cancer (2024-2032) ($MN)
  • Table 18 Global Advanced Cancer Diagnostics Market Outlook, By Cervical Cancer (2024-2032) ($MN)
  • Table 19 Global Advanced Cancer Diagnostics Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
  • Table 20 Global Advanced Cancer Diagnostics Market Outlook, By Ovarian Cancer (2024-2032) ($MN)
  • Table 21 Global Advanced Cancer Diagnostics Market Outlook, By Prostate Cancer (2024-2032) ($MN)
  • Table 22 Global Advanced Cancer Diagnostics Market Outlook, By Other Cancers (2024-2032) ($MN)
  • Table 23 Global Advanced Cancer Diagnostics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 24 Global Advanced Cancer Diagnostics Market Outlook, By Imaging Techniques (2024-2032) ($MN)
  • Table 25 Global Advanced Cancer Diagnostics Market Outlook, By MRI (2024-2032) ($MN)
  • Table 26 Global Advanced Cancer Diagnostics Market Outlook, By PET/CT (2024-2032) ($MN)
  • Table 27 Global Advanced Cancer Diagnostics Market Outlook, By CT Scan (2024-2032) ($MN)
  • Table 28 Global Advanced Cancer Diagnostics Market Outlook, By Ultrasound (2024-2032) ($MN)
  • Table 29 Global Advanced Cancer Diagnostics Market Outlook, By Mammography (2024-2032) ($MN)
  • Table 30 Global Advanced Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2024-2032) ($MN)
  • Table 31 Global Advanced Cancer Diagnostics Market Outlook, By PCR (2024-2032) ($MN)
  • Table 32 Global Advanced Cancer Diagnostics Market Outlook, By Microarrays (2024-2032) ($MN)
  • Table 33 Global Advanced Cancer Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 34 Global Advanced Cancer Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2024-2032) ($MN)
  • Table 35 Global Advanced Cancer Diagnostics Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 36 Global Advanced Cancer Diagnostics Market Outlook, By ELISA (2024-2032) ($MN)
  • Table 37 Global Advanced Cancer Diagnostics Market Outlook, By Immunohistochemistry (IHC) (2024-2032) ($MN)
  • Table 38 Global Advanced Cancer Diagnostics Market Outlook, By Liquid Biopsy (2024-2032) ($MN)
  • Table 39 Global Advanced Cancer Diagnostics Market Outlook, By Circulating Tumor Cells (CTCs) (2024-2032) ($MN)
  • Table 40 Global Advanced Cancer Diagnostics Market Outlook, By Circulating Tumor DNA (ctDNA) (2024-2032) ($MN)
  • Table 41 Global Advanced Cancer Diagnostics Market Outlook, By Exosomes (2024-2032) ($MN)
  • Table 42 Global Advanced Cancer Diagnostics Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 43 Global Advanced Cancer Diagnostics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 44 Global Advanced Cancer Diagnostics Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 45 Global Advanced Cancer Diagnostics Market Outlook, By Distributors & Dealers (2024-2032) ($MN)
  • Table 46 Global Advanced Cancer Diagnostics Market Outlook, By Online Platforms (2024-2032) ($MN)
  • Table 47 Global Advanced Cancer Diagnostics Market Outlook, By Application (2024-2032) ($MN)
  • Table 48 Global Advanced Cancer Diagnostics Market Outlook, By Early Cancer Screening (2024-2032) ($MN)
  • Table 49 Global Advanced Cancer Diagnostics Market Outlook, By Recurrence & Minimal Residual Disease (MRD) Detection (2024-2032) ($MN)
  • Table 50 Global Advanced Cancer Diagnostics Market Outlook, By Diagnostic & Prognostic Testing (2024-2032) ($MN)
  • Table 51 Global Advanced Cancer Diagnostics Market Outlook, By Companion Diagnostics (2024-2032) ($MN)
  • Table 52 Global Advanced Cancer Diagnostics Market Outlook, By Therapy Selection & Monitoring (2024-2032) ($MN)
  • Table 53 Global Advanced Cancer Diagnostics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 54 Global Advanced Cancer Diagnostics Market Outlook, By End User (2024-2032) ($MN)
  • Table 55 Global Advanced Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 56 Global Advanced Cancer Diagnostics Market Outlook, By Ambulatory Care Centers (2024-2032) ($MN)
  • Table 57 Global Advanced Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 58 Global Advanced Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2024-2032) ($MN)
  • Table 59 Global Advanced Cancer Diagnostics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.